A Phase II Evaluation of Nivolumab, A Fully Human Antibody against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer - Regional Cancer Care Associates LLC

Clinical Trials

A Phase II Evaluation of Nivolumab, A Fully Human Antibody against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer

Type of Cancer
Gynecologic
Locations
Hackensack
Sponsor
NRG Oncology
Protocol Number
NRG Oncology GY002
Cancer Diagnosis
To Learn More Call
201-510-0910